Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

NINTEDANIB TEVA 150 MG CAPSULAS BLANDAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/NINTEDANIB TEVA 150 MG CAPSULAS BLANDAS EFG

Approved

STANDARD

NINTEDANIB TEVA 150 MG CAPSULAS BLANDAS EFG

Teva Pharma S.L.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 8, 2024
Approval ID: ed3c769b3a22ca04
Company: Teva Pharma S.L.U.
Type: Standard

Approval Details

Approval Id: ed3c769b3a22ca04
Drug Cima Aemps Name: NINTEDANIB TEVA 150 MG CAPSULAS BLANDAS EFG
Register Number: 89431
Holder Company Name: Teva Pharma S.L.U.
Marketing Company Name: Teva Pharma S.L.U.
Authorization Date: 2024-03-08
Dosage Form: CÁPSULA BLANDA
Dose: 150 mg
Route Of Administration: VÍA ORAL
Prescription Type: Uso Hospitalario
Commercialized: No
Company Name: Teva Pharma S.L.U.

Active Ingredients

NINTEDANIB ESILATO

180,6 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 8, 2024

Approval ID

ed3c769b3a22ca04

Type

Standard

Back to CIMA-AEMPS Approvals